Abstract: Provided herein are novel substituted phenyl oxazolidinones and to processes for the synthesis thereof. Also provided are pharmaceutical compositions comprising one or more compounds described herein The compounds described can be useful antimicrobial agents, which can be effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci, as well as, anaerobic organisms, such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms, such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

Abstract: This invention relates to combination therapy for the treatment of lower urinary tract symptoms (LUTS) associated with or without benign prostatic hyperplasia (BPH). The combination therapy comprises of tailored 1 adrenoceptor antagonist, which is selective for 1a over 1b subtype but non-selective for 1a over 1d subtype, in combination with muscarinic receptor antagonist, preferably bladder selective antagonist and optionally included 5-reductase inhibitor for relief of LUTS in a mammal with or without BPH.

Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

Abstract: Methods and systems for database storage allowing subscriber entities to create specialized interfaces for storing different classes of information based on subscribed-defined categories and parameters, allowing for efficient search and retrieval of the information by users using the subscriber-defined categories and parameters. A method for processing a search request comprises receiving from a user a set of search terms, retrieving from a database a set of records satisfying the search terms, sending the search terms to one or more suppliers as indicated by supplier links associated with the records, receiving a set of results from the one or more suppliers, and sending the set of results to the user.

Abstract: This invention generally relates to macrolides, more particularly, the invention relates to 3-N-substituted-3-O-substituted erythronolide A derivatives, which are antibacterial agents effective against gram positive or gram negative bacteria and atypical pathogens. The compounds of this invention are more particularly effective against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating bacterial infection.

Abstract: This invention relates to ?1a and/or ?1d adrenergic receptor antagonists of formula 1 Compounds disclosed herein can function as ?1a and/or ?1d adrenergic receptor antagonists and can be used for the treatment of diseases or disorders mediated through ?1a and/or ?1d adrenergic receptors. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia and related symptoms thereof. Compounds disclosed herein can also be used for the treatment of lower urinary tract symptoms associated with or without benign prostatic hyperplasia. The invention also relates to a process for the preparation of compounds disclosed herein, pharmaceutical compositions containing these compounds and the methods of treating diseases or disorders mediated through ?1a and/or ?1d receptors.

Abstract: The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R2, R4 and R5 is a heterocycle and with the further provision that if R2 is not a heterocycle then either R4 or R5 alone is not unsubstituted pyridyl, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0]hexanes, as well as pharmaceutical compositions containing such compounds and methods of treating diseases mediated through muscarinic receptors.

Abstract: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of repaglinide.

Abstract: Novel carboximide derivatives, which selectively inhibit binding to the ?1A adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign prostatic hyperplasia.

Abstract: Certain derivatives of azasugars, useful in the treatment of cancer, are presented. This invention also relates to pharmacological compositions containing the compounds of present invention and treatment of cancer, including tumor or other neoplasm, with an azasugar.

Abstract: The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I and their corresponding lactones.

Abstract: The present invention relates to novel azole derivatives of Formula I, as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.

Abstract: The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I and their corresponding lactones.

Abstract: This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0] hexanes, and 2,4,6-trisubstituted derivatives. The invention also relates to pharmaceutical compositions containing the compounds and the methods of treating the diseases mediated through muscarinic receptors.

Abstract: The present invention relates to triazine derivatives as cell adhesion inhibitors. The compounds of this invention can be useful inter alia, for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis. The compounds can be used to formulate pharmacological compositions, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds are also provided herein.

Abstract: The present invention relates to derivatives of 2,2,4-trisubstituted tetrahydrofuran as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.

Abstract: Novel ?,?-dicarboximide derivatives which selectively inhibit binding to the ?-,1A? adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign prostatic hyperplasia.

Abstract: The present invention relates to novel azole derivatives of Formula I, as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.